BUZZ-UniQure extends eye-watering rally ahead of planned $200 mln share offering
I'm PortAI, I can summarize articles.
U.S.-listed shares of Dutch drugmaker UniQure surged approximately 248% to $47.50 following positive results from an early-to-mid-stage trial of its experimental gene therapy for Huntington's disease. The company plans a $200 million share offering and currently has about 54.9 million shares outstanding, with a market cap of around $2.6 billion. Short interest in UniQure shares has nearly tripled since the beginning of 2025, with about 8.3 million shares sold short as of September 25, representing approximately 16% of the public float.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments